SG Americas Securities LLC Sells 47,765 Shares of Medpace Holdings, Inc. $MEDP

SG Americas Securities LLC reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 79.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,379 shares of the company’s stock after selling 47,765 shares during the quarter. SG Americas Securities LLC’s holdings in Medpace were worth $5,944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares in the last quarter. Franklin Resources Inc. lifted its stake in Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank bought a new position in shares of Medpace during the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after purchasing an additional 166,654 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ:MEDP opened at $527.07 on Monday. The firm has a market capitalization of $15.05 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 2.67 and a beta of 1.18. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The business has a 50 day simple moving average of $451.19 and a 200-day simple moving average of $496.65.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the previous year, the company posted $3.67 EPS. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MEDP shares. Robert W. Baird reduced their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada dropped their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Barclays reduced their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Finally, Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.